Stock A086450 DONGKOOK PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings DongKook Pharmaceutical Co., Ltd.

Equities

A086450

KR7086450004

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 24/06/2024 am IST 		5-day change 1st Jan Change
17,590 KRW -1.01% Intraday chart for DongKook Pharmaceutical Co., Ltd. -3.77% +8.85%
16/05 DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/03 DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DONGKOOK PHARMACEUTICAL CO., LTD. Stock DongKook Pharmaceutical Co., Ltd.
+8.85% 558M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+47.26% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
B-
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.40% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.64% 229B
A+
NOVARTIS AG Stock Novartis AG
+12.98% 219B
B-
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. A086450 Stock
  4. Ratings DongKook Pharmaceutical Co., Ltd.